View Clinical Trial (Medical Research Study)

Compare Effects of a Soluble Fiber on Weight and Blood Cholesterol - NCT00682916-95817(Clinical Trial 222520)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Sacramento
State:  
CA
Zip Code: 95817
Conditions: Obesity
Purpose: Obesity and type 2 diabetes have clearly been linked together and identified as epidemics in much of the developed world. Historically several different dietary fibers have been used as means of reducing body weight and the related development of type 2 diabetes. These studies have generated mixed, if not inconsistent, results suggesting that none of these fibers promise a solution to either of these two conditions. We are proposing to investigate the effects of including a new soluble fiber, a-cyclodextrin, FBCx® (to be called Y288 in this study), into the diet of adult overweight volunteers.
Study summary: The overall aim is to investigate the effectiveness of a soluble dietary fiber, FBCx®, on weight loss and/or weight management, and blood lipid levels in overweight humans.
Criteria: Inclusion Criteria: - 30 men and 30 women - Age 18- 65 years - BMI 25.0 - 32.0 Kg/m² - fasting glucose <126 mg/dL - Blood pressure < 140/85 mm Hg. Hypertension on stable drug regimen using 2 or fewer antihypertensives will be acceptable. - Total plasma cholesterol <240 mg/dl, LDL-cholesterol <160 and triglycerides <400 mg/dl. Hyperlipidemia on a stable medication regimen using single anti-hyperlipidemic drug acceptable. Exclusion Criteria: - Pregnant women, women who plan to become pregnant during the study period - Women who have given birth within the previous 12 months - Lactating women - History or presence of Type 2 diabetes; kidney disease; (creatinine >1.4); liver disease (X2 fold increase in AST or ALT); gout; cancer; untreated thyroid disease; gastrointestinal disease; other metabolic diseases or malabsorption syndromes - Habitual low-fat intake (less than 20%) - History of eating disorder - Subjects who have lost 10% of body weight within the last 12 months or who plan to initiate a weight loss program - Use of prescription or over-the counter anti-obesity medications or supplements (phenylpropanolamine, ephedrine, caffeine) for at least 6 months prior of study. - Subjects with pacemakers will not participate in bioimpedance studies but will go through all the other testing.
Study is available at: UC Davis
Sacramento, CA 95817
United States

Primary Contact:
Melinda Posas, BS
Email: velayo.melinda@gmail.com
Phone: 916-734-4777

Secondary Contact:
Melinda Posas, BS
Email: velayo.melinda@gmail.com
Phone: 916-734-4747
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.